03681.HK
SinoMab BioScience Limited
HKSE · Healthcare · Biotechnology · HK
HKD 1.07
+4.90%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -30.9%
- EBIT
- -19.5%
- EPS
- +0.6%
- Free cash flow
- -91.1%
- Operating cash flow
- +7.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +45.7%
- EBIT
- +22.7%
- Net income
- +44.8%
- EPS
- +50.9%
- Free cash flow
- +44.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026